The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3

CD123 became a therapeutic target for acute myelocytic leukemia(AML) because of its overexpression only on AML stem cells. It is α subunit of interleukin-3 (multi-CSF, IL3) receptor. Lidamycin(LDM) is a novel antibiotic composed of an apoprotein (LDP) and a chromophore (AE). We cloned, expressed and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Zhang, Yanjun, Liu, Rong, Fan, Dongmei, Shi, Rizan, Yang, Ming, Miao, Qingfang, Deng, Zhao-Qun, Qian, Jun, Zhen, Yongsu, Xiong, Dongsheng, Wang, Jianxiang
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4846095/
https://ncbi.nlm.nih.gov/pubmed/26186454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1071733
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados